Navamedic ASA
F:N1A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Navamedic ASA
F:N1A
|
NO |
|
G
|
Gas Plus SpA
XBER:T9O
|
IT |
|
T
|
Tazmo Co Ltd
TSE:6266
|
JP |
|
Sosandar PLC
F:HXKB
|
UK |
|
Inhibrx Inc
F:1RK
|
US |
|
F
|
Fauji Fertilizer Company Ltd
KAR:FFC
|
PK |
Navamedic ASA
Navamedic ASA is a Nordic healthcare company that markets and sells prescription medicines, medical nutrition products, and other healthcare products in selected European markets. It does not mainly discover drugs itself; instead, it buys rights to products from other developers and brings them to doctors, hospitals, pharmacies, and consumers in the countries where it has distribution rights. The company makes money by selling these products through its own sales and distribution network and, in some cases, by holding rights to market a product in a specific country or region. Its customers include hospitals, clinics, pharmacies, and retail channels, depending on the product. This makes Navamedic a specialist middleman in the pharmaceutical value chain: it connects product owners with local healthcare markets that need established, approved products. What sets the business apart is its focus on niche healthcare categories and on the practical work of registering, launching, and distributing products across Nordic and nearby markets. That model can be attractive because it relies on know-how in regulation, market access, and local sales rather than on running a large drug research program.
Navamedic ASA is a Nordic healthcare company that markets and sells prescription medicines, medical nutrition products, and other healthcare products in selected European markets. It does not mainly discover drugs itself; instead, it buys rights to products from other developers and brings them to doctors, hospitals, pharmacies, and consumers in the countries where it has distribution rights.
The company makes money by selling these products through its own sales and distribution network and, in some cases, by holding rights to market a product in a specific country or region. Its customers include hospitals, clinics, pharmacies, and retail channels, depending on the product. This makes Navamedic a specialist middleman in the pharmaceutical value chain: it connects product owners with local healthcare markets that need established, approved products.
What sets the business apart is its focus on niche healthcare categories and on the practical work of registering, launching, and distributing products across Nordic and nearby markets. That model can be attractive because it relies on know-how in regulation, market access, and local sales rather than on running a large drug research program.
